Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Poliovirus vaccine inactivated Intravacc/Sinovac/WHO (Primary)
  • Indications Poliomyelitis
  • Focus Pharmacodynamics; Registrational
  • Sponsors Sinovac Biotech

    • Most Recent Events

    • 16 Apr 2019 Results presented in the Sinovac Biotech media release.
    • 08 Apr 2019 Primary endpoint has been met. (The seroconversion rates (SCRs) of each group after primary immunization.) published in the Journal of Infectious Diseases.
    • 08 Apr 2019 Results assessing sIPV demonstrating an immunogenicity profile noninferior to that of the conventional IPV, also as a good safety profile published in the Journal of Infectious Diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top